Sergey V. Kotov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sergey V. Kotov has a total of 371 co-authors. Here are the top co-authors by number of shared publications:
- Elena V. Isakova
M.F. Vladimirsky Moscow Regional Research Clinical Institute
33 shared publications E. V. Isakova
Vladimirsky Moscow Regional Clinical Research Institute, Moscow, Russia
13 shared publications- I. G. Rudakova
Vladimirsky Moscow Regional Research Clinical Institute, Moscow, Russia
10 shared publications - Olga P. Sidorova
Vladimirsky Moscow Regional Research Clinical Institute
9 shared publications - Arina V. Zinkina-Orikhan
BIOCAD
8 shared publications - Valentina A. Zenina
Vladimirskiy Moscow Regional Research Clinical Institute
8 shared publications
Latest Publications
- 13 November 2026
- Published by Publishing House ABV Press in Russian Journal of Child Neurology
- Vol. 21 (3)
Dynamics of motor function changes in children with spinal muscular atrophy under pathogenetic therapy
Spinal muscular atrophy is a progressive and severe neuromuscular disorder and represents one of the causes of early disability and infant mortality. When SMA is suspected in a child, prompt diagnosis and timely initiation of treatment are essential, as subsequent health-related quality of life depends directly on early diagnosis and timely therapeutic intervention. Currently, several disease-modifying therapies have been developed that can influence the progression of the disease and improve the patient’s health-related quality of life. During pathogenetic treatment, changes in patients’ motor function can be observed. The most reliable way to assess this motor function dynamics is through standardized motor scales.
- 13 November 2026
- Published by Publishing House ABV Press in Russian Journal of Child Neurology
- Vol. 21 (3)
Dynamics of motor function changes in children with spinal muscular atrophy under pathogenetic therapy
Spinal muscular atrophy is a progressive and severe neuromuscular disorder and represents one of the causes of early disability and infant mortality. When SMA is suspected in a child, prompt diagnosis and timely initiation of treatment are essential, as subsequent health-related quality of life depends directly on early diagnosis and timely therapeutic intervention. Currently, several disease-modifying therapies have been developed that can influence the progression of the disease and improve the patient’s health-related quality of life. During pathogenetic treatment, changes in patients’ motor function can be observed. The most reliable way to assess this motor function dynamics is through standardized motor scales.
- 1 October 2026
- Published by MEDIKON LLC in Comorbidity neurology
- Vol. 3 (3)
Cognitive Health Levels and Attitudes Towards Illness in Patients Recovering from Ischemic Stroke
INTRODUCTION. Rehabilitation of patients after a cerebral stroke is an urgent problem of neurorehabilitation. The patient's participation in the treatment process depends on their psychological state, types of attitude towards the disease, and level of motivation. AIM. To study of the influence of attitude towards illness and motivation for recovery on the effectiveness of neurorehabilitation after cerebral stroke depending on the cognitive level. MATERIALS AND METHODS. The study included 48 patients following a cerebral stroke. The patients underwent comprehensive rehabilitation using the multimodal stimulation (MMS) method. Based on their baseline cognitive status assessed via the MoCA scale, the patients were divided into two groups: those with cognitive impairment and those without. Scales were used to assess emotional and cognitive status and motor function, as well as to determine the patient's attitude toward the illness. RESULTS AND DISCUSSION. During rehabilitation, patients with cognitive impairments showed statistically significant changes in assessments of the cognitive, emotional, and motor domains. Patients without cognitive impairments demonstrated the safety of the treatment and improvements in cognitive and motor skills. Among patients with cognitive impairments, all 12 types of attitude toward the disease were identified in various combinations using the TOBOL method. Patients without cognitive impairments exhibited the harmonious, ergopathic, anosognosic, neurasthenic, and sensitive types of attitude toward the disease. In both groups, the ergopathic type of attitude toward the disease was the most common. A statistically significant improvement in indicators was observed primarily in patients with a "pure" type of attitude toward the illness. A trend was identified wherein types characterized by preserved psychological and social adaptation exhibited the highest baseline scores and showed positive dynamics during treatment, whereas patients with maladaptive types of response to the illness showed the lowest scores. The majority of patients demonstrated an optimal or moderately high level of motivation, which served as a favorable prognostic factor for rehabilitation. CONCLUSION. In the study conducted, the attitude toward the illness was a significant predictor of the effectiveness of comprehensive rehabilitation. Patients without marked impairments in psychological and social adaptation demonstrated higher baseline scores on the scales used and better progress during the rehabilitation process. KEYWORDS: cerebral stroke, comprehensive rehabilitation, psychological factors, type of attitude towards the disease, cognitive impairments
- 1 October 2026
- Published by MEDIKON LLC in Comorbidity neurology
- Vol. 3 (3)
Cognitive Health Levels and Attitudes Towards Illness in Patients Recovering from Ischemic Stroke
INTRODUCTION. Rehabilitation of patients after a cerebral stroke is an urgent problem of neurorehabilitation. The patient's participation in the treatment process depends on their psychological state, types of attitude towards the disease, and level of motivation. AIM. To study of the influence of attitude towards illness and motivation for recovery on the effectiveness of neurorehabilitation after cerebral stroke depending on the cognitive level. MATERIALS AND METHODS. The study included 48 patients following a cerebral stroke. The patients underwent comprehensive rehabilitation using the multimodal stimulation (MMS) method. Based on their baseline cognitive status assessed via the MoCA scale, the patients were divided into two groups: those with cognitive impairment and those without. Scales were used to assess emotional and cognitive status and motor function, as well as to determine the patient's attitude toward the illness. RESULTS AND DISCUSSION. During rehabilitation, patients with cognitive impairments showed statistically significant changes in assessments of the cognitive, emotional, and motor domains. Patients without cognitive impairments demonstrated the safety of the treatment and improvements in cognitive and motor skills. Among patients with cognitive impairments, all 12 types of attitude toward the disease were identified in various combinations using the TOBOL method. Patients without cognitive impairments exhibited the harmonious, ergopathic, anosognosic, neurasthenic, and sensitive types of attitude toward the disease. In both groups, the ergopathic type of attitude toward the disease was the most common. A statistically significant improvement in indicators was observed primarily in patients with a "pure" type of attitude toward the illness. A trend was identified wherein types characterized by preserved psychological and social adaptation exhibited the highest baseline scores and showed positive dynamics during treatment, whereas patients with maladaptive types of response to the illness showed the lowest scores. The majority of patients demonstrated an optimal or moderately high level of motivation, which served as a favorable prognostic factor for rehabilitation. CONCLUSION. In the study conducted, the attitude toward the illness was a significant predictor of the effectiveness of comprehensive rehabilitation. Patients without marked impairments in psychological and social adaptation demonstrated higher baseline scores on the scales used and better progress during the rehabilitation process. KEYWORDS: cerebral stroke, comprehensive rehabilitation, psychological factors, type of attitude towards the disease, cognitive impairments
- 4 September 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (8)
Success rates of revascularization methods in ischemic stroke in clinical practice
Objective. To compare the success rates of various revascularization methods in patients presenting with ischemic stroke (IS) in a real-world practice. Material and methods. An open-label prospective observational study was conducted involving 225 patients diagnosed with IS. The patients were categorized into three distinct groups: Group 1 (67.1% of participants) received systemic thrombolytic therapy [TLT], Group 2 (15.6% of participants) received intravascular thrombectomy (IVTE), and Group 3 (17.3% of participants) received combined TLT+IVTE, referred to as bridge therapy. The assessment of neurological status was conducted using the National Institutes of Health Stroke Scale (NIHSS), functional activity was evaluated according to the modified Rankin Scale (mRs), mobility was measured based on the Rivermead Mobility Index (RMI), and the completeness of perfusion recovery was determined using the Thrombolysis in Cerebral Infarction (TICI) classification for Groups 2 and 3. Functional recovery was evaluated after 6 months using the Barthel Index (BI). Results. Demographic characteristics across the groups were comparable. Statistically significant differences in the timing of revascularization were observed: Groups 1 and 3 received treatment within approximately 2.5 hours, whereas Group 2 received treatment within 6 hours. Baseline stroke severity, as measured by the NIHSS, was significantly higher in Groups 2 and 3 (p<0.002). The TICI scores of 2b-3 were noted in 74.3% of patients in Group 2 and 79.5% in Group 3, reflecting the substantial technical success rates of endovascular interventions. At discharge, patients in Group 1 exhibited the greatest reduction in neurological deficit (p=0.011). Independence in daily activities (rated 0—2 on the mRs) was achieved by 28.5% of patients in Group 1, 8.6% in Group 2, and 12.8% in Group 3. The mortality rate over 6 months was 24.5% in Group 1, 51.4% in Group 2, and 33.3% in Group 3 (p=0.002 between Groups 1 and 2). The BI at the six-month mark was significantly higher in Group 1 (90 [60; 100]) compared to Groups 2 (60 [50; 85]) and 3 (65 [50; 97.5]). Conclusions. The findings suggest that systemic TLT, particularly in patients with less severe strokes and timely treatment initiation, is associated with the most favorable outcomes. In contrast, IVTE and combination therapy (bridge therapy) administered to patients with NIHSS scores exceeding 10 and/or large vessel occlusions demonstrate comparable technical success rates but yield less favorable clinical outcomes. Critical determinants influencing outcomes include the duration from symptom onset to intervention and baseline stroke severity.
- 4 September 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (8)
Success rates of revascularization methods in ischemic stroke in clinical practice
Objective. To compare the success rates of various revascularization methods in patients presenting with ischemic stroke (IS) in a real-world practice. Material and methods. An open-label prospective observational study was conducted involving 225 patients diagnosed with IS. The patients were categorized into three distinct groups: Group 1 (67.1% of participants) received systemic thrombolytic therapy [TLT], Group 2 (15.6% of participants) received intravascular thrombectomy (IVTE), and Group 3 (17.3% of participants) received combined TLT+IVTE, referred to as bridge therapy. The assessment of neurological status was conducted using the National Institutes of Health Stroke Scale (NIHSS), functional activity was evaluated according to the modified Rankin Scale (mRs), mobility was measured based on the Rivermead Mobility Index (RMI), and the completeness of perfusion recovery was determined using the Thrombolysis in Cerebral Infarction (TICI) classification for Groups 2 and 3. Functional recovery was evaluated after 6 months using the Barthel Index (BI). Results. Demographic characteristics across the groups were comparable. Statistically significant differences in the timing of revascularization were observed: Groups 1 and 3 received treatment within approximately 2.5 hours, whereas Group 2 received treatment within 6 hours. Baseline stroke severity, as measured by the NIHSS, was significantly higher in Groups 2 and 3 (p<0.002). The TICI scores of 2b-3 were noted in 74.3% of patients in Group 2 and 79.5% in Group 3, reflecting the substantial technical success rates of endovascular interventions. At discharge, patients in Group 1 exhibited the greatest reduction in neurological deficit (p=0.011). Independence in daily activities (rated 0—2 on the mRs) was achieved by 28.5% of patients in Group 1, 8.6% in Group 2, and 12.8% in Group 3. The mortality rate over 6 months was 24.5% in Group 1, 51.4% in Group 2, and 33.3% in Group 3 (p=0.002 between Groups 1 and 2). The BI at the six-month mark was significantly higher in Group 1 (90 [60; 100]) compared to Groups 2 (60 [50; 85]) and 3 (65 [50; 97.5]). Conclusions. The findings suggest that systemic TLT, particularly in patients with less severe strokes and timely treatment initiation, is associated with the most favorable outcomes. In contrast, IVTE and combination therapy (bridge therapy) administered to patients with NIHSS scores exceeding 10 and/or large vessel occlusions demonstrate comparable technical success rates but yield less favorable clinical outcomes. Critical determinants influencing outcomes include the duration from symptom onset to intervention and baseline stroke severity.
- 30 July 2026
- Published by Publishing House ABV Press in Russian Journal of Child Neurology
- Vol. 21 (2) , 97-102
Autoimmune encephalitis and demyelinating diseases: intersections
This article examines the growing conceptual and clinical convergence between autoimmune encephalitis (AE) and demyelinating diseases (DD) of the central nervous system. The author emphasizes that the traditional boundaries between these disease groups are becoming increasingly blurred due to shared immunopathological mechanisms leading to autoimmune damage to the central nervous system. The article begins with clear definitions: AE are characterized by an immune attack on neuronal antigens (synaptic receptors, intracellular proteins), which clinically manifests as acute neuropsychiatric symptoms such as psychosis, seizures, cognitive impairment, and dyskinesias. Meanwhile, DD, a classic example of which is multiple sclerosis, primarily affect the myelin sheath, leading to focal neurological deficits (paresis, sensory disturbances, optic neuritis). The focus is on the intersection points and overlap syndromes, where patients exhibit features of both disease groups simultaneously. Key examples include: myelin oligodendrocyte glycoprotein antibody-associated disease, which can manifest as both a demyelinating disease (e.g., optic neuritis) and an encephalitis with cortical lesions; anti-NMDAR encephalitis, which in rare cases can coexist with or precede multiple sclerosis; AQP4-positive neuromyelitis optica, severe forms of which, involving the brainstem or hypothalamus, can phenotypically mimic encephalitis. The author provides a detailed comparative table, highlighting the differences and similarities between AE and DD in terms of parameters such as the primary immune target, leading symptoms, magnetic resonance imaging findings, laboratory markers, prognosis, and triggers. The section on treatment notes that in the acute phase, therapy for both groups is similar and includes pulse corticosteroid therapy, plasmapheresis, and intravenous immunoglobulin aimed at suppressing the autoimmune response. However, maintenance therapy differs fundamentally: in AE, the focus is on identifying and eliminating the trigger (e.g., tumor) and using second-line drugs (rituximab), whereas in DD, the primary goal is long-term relapse prevention with disease-modifying therapies specific to each disease (e.g., ocrelizumab in multiple sclerosis, eculizumab in AQP4-positive neuromyelitis optica). The paper concludes that AE and DD represent a continuum of immune-mediated central nervous system lesions. The importance of comprehensive diagnostics using expanded antibody panels and neuroimaging methods to identify overlap syndromes is emphasized, as early and adequate treatment is critical to improving prognosis and minimizing irreversible damage. Future research should be aimed at developing personalized therapeutic approaches.
- 30 July 2026
- Published by Publishing House ABV Press in Russian Journal of Child Neurology
- Vol. 21 (2) , 97-102
Autoimmune encephalitis and demyelinating diseases: intersections
This article examines the growing conceptual and clinical convergence between autoimmune encephalitis (AE) and demyelinating diseases (DD) of the central nervous system. The author emphasizes that the traditional boundaries between these disease groups are becoming increasingly blurred due to shared immunopathological mechanisms leading to autoimmune damage to the central nervous system. The article begins with clear definitions: AE are characterized by an immune attack on neuronal antigens (synaptic receptors, intracellular proteins), which clinically manifests as acute neuropsychiatric symptoms such as psychosis, seizures, cognitive impairment, and dyskinesias. Meanwhile, DD, a classic example of which is multiple sclerosis, primarily affect the myelin sheath, leading to focal neurological deficits (paresis, sensory disturbances, optic neuritis). The focus is on the intersection points and overlap syndromes, where patients exhibit features of both disease groups simultaneously. Key examples include: myelin oligodendrocyte glycoprotein antibody-associated disease, which can manifest as both a demyelinating disease (e.g., optic neuritis) and an encephalitis with cortical lesions; anti-NMDAR encephalitis, which in rare cases can coexist with or precede multiple sclerosis; AQP4-positive neuromyelitis optica, severe forms of which, involving the brainstem or hypothalamus, can phenotypically mimic encephalitis. The author provides a detailed comparative table, highlighting the differences and similarities between AE and DD in terms of parameters such as the primary immune target, leading symptoms, magnetic resonance imaging findings, laboratory markers, prognosis, and triggers. The section on treatment notes that in the acute phase, therapy for both groups is similar and includes pulse corticosteroid therapy, plasmapheresis, and intravenous immunoglobulin aimed at suppressing the autoimmune response. However, maintenance therapy differs fundamentally: in AE, the focus is on identifying and eliminating the trigger (e.g., tumor) and using second-line drugs (rituximab), whereas in DD, the primary goal is long-term relapse prevention with disease-modifying therapies specific to each disease (e.g., ocrelizumab in multiple sclerosis, eculizumab in AQP4-positive neuromyelitis optica). The paper concludes that AE and DD represent a continuum of immune-mediated central nervous system lesions. The importance of comprehensive diagnostics using expanded antibody panels and neuroimaging methods to identify overlap syndromes is emphasized, as early and adequate treatment is critical to improving prognosis and minimizing irreversible damage. Future research should be aimed at developing personalized therapeutic approaches.
- Open Access
- 30 June 2026
- Published by ECO-Vector LLC (Publications) in Annals of Clinical and Experimental Neurology
- Vol. 20 (2) , 26-35
Divozilimab in neuromyelitis optica spectrum disorders: one-year interim analysis of the AQUARELLE clinical trial
Introduction. Divozilimab, a humanized, afucosylated monoclonal antibody that targets CD20, has been approved to treat multiple sclerosis, neuromyelitis optica spectrum disorders (NMOSD), and systemic sclerosis. The AQUARELLE clinical trial evaluates the efficacy and safety of divozilimab in patients with NMOSD. Aim. The study aimed to evaluate the efficacy and safety of divozilimab during the first year of treatment in patients with NMOSD. Materials and methods. The AQUARELLE open-label clinical trial enrolled 105 patients with NMOSD. All patients received 500 mg of divozilimab via intravenous infusion every 24 weeks. After 1 year of treatment, the following key parameters were evaluated: the annualized relapse rate (ARR), time to first relapse compared to a historical control group (the placebo group from the SakuraStar study), the proportion of patients with confirmed disability worsening (CDW), changes in Expanded Disability Status Scale (EDSS) scores, and safety parameters. Results. The ARR in patients with NMOSD who received divozilimab for one year was 0.104 (95% confidence interval [CI], 0.056–0.193), and 90.5% of patients had no confirmed relapses. The calculated weighted ratio of ARR (90% CI) for divozilimab to the historical placebo (SAkuraStar) was 0.237 (90% CI: 0.084–0.672), demonstrating superiority of divozilimab. The EDSS score remained stable, and no cases of CDW were reported. Adverse events (AEs) were observed in 76% of patients, most of which were mild or moderate in severity. The most common adverse drug reactions were lymphopenia (21%), leukopenia (11.4%), neutropenia (12.4%), and infusion-related reactions (5.7%). No serious adverse reactions were reported. Conclusion. The 1-year interim results of divozilimab therapy in patients with NMOSD from the AQUARELLE clinical trial demonstrate the sustained efficacy of therapy in reducing both the rate and risk of NMOSD relapses. Additionally, the safety profile was consistent with that expected for anti-B-cell therapy.
- 30 June 2026
- Published by ECO-Vector LLC (Publications) in Annals of Clinical and Experimental Neurology
- Vol. 20 (2) , 26-35
Open AccessDivozilimab in neuromyelitis optica spectrum disorders: one-year interim analysis of the AQUARELLE clinical trial
Introduction. Divozilimab, a humanized, afucosylated monoclonal antibody that targets CD20, has been approved to treat multiple sclerosis, neuromyelitis optica spectrum disorders (NMOSD), and systemic sclerosis. The AQUARELLE clinical trial evaluates the efficacy and safety of divozilimab in patients with NMOSD. Aim. The study aimed to evaluate the efficacy and safety of divozilimab during the first year of treatment in patients with NMOSD. Materials and methods. The AQUARELLE open-label clinical trial enrolled 105 patients with NMOSD. All patients received 500 mg of divozilimab via intravenous infusion every 24 weeks. After 1 year of treatment, the following key parameters were evaluated: the annualized relapse rate (ARR), time to first relapse compared to a historical control group (the placebo group from the SakuraStar study), the proportion of patients with confirmed disability worsening (CDW), changes in Expanded Disability Status Scale (EDSS) scores, and safety parameters. Results. The ARR in patients with NMOSD who received divozilimab for one year was 0.104 (95% confidence interval [CI], 0.056–0.193), and 90.5% of patients had no confirmed relapses. The calculated weighted ratio of ARR (90% CI) for divozilimab to the historical placebo (SAkuraStar) was 0.237 (90% CI: 0.084–0.672), demonstrating superiority of divozilimab. The EDSS score remained stable, and no cases of CDW were reported. Adverse events (AEs) were observed in 76% of patients, most of which were mild or moderate in severity. The most common adverse drug reactions were lymphopenia (21%), leukopenia (11.4%), neutropenia (12.4%), and infusion-related reactions (5.7%). No serious adverse reactions were reported. Conclusion. The 1-year interim results of divozilimab therapy in patients with NMOSD from the AQUARELLE clinical trial demonstrate the sustained efficacy of therapy in reducing both the rate and risk of NMOSD relapses. Additionally, the safety profile was consistent with that expected for anti-B-cell therapy.
- 20 June 2026
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 18 (3)
Predictors of treatment efficacy in mesial temporal lobe epilepsy and focal epilepsies of other localisations
Mesial temporal lobe epilepsy (MTLE) is characterised by a high rate of drug resistance; however, it remains difficult to predict an individual’s response to treatment at an early stage. There is a need to optimise approaches to identifying predictors of treatment efficacy not only for MTLE but also for focal epilepsies of other localisation (FEOL). Objective: to identify clinical, anamnestic and neuroimaging predictors of response to drug therapy in patients with MTLE and FEOL, and to identify factors that do not have independent prognostic value. Material and methods. A retrospective analysis of a database of patients with focal epilepsy was conducted. Binary logistic regression was used to develop a prognostic model. Results. In the MTLE group (n=297), remission was achieved in 29% of patients, which is significantly lower than in the FEOL group (n=340) – 38.5% (p0.05). According to binary logistic regression (n=540; 36.1% – no positive effect, 63.9% – positive effect), after stepwise exclusion of non-informative predictors, three independent factors remained in the final model. Rare attacks increased the odds of a positive clinical effect (remission or a reduction in attack frequency by more than 50%): the odds ratio (OR) for the categories ‘several times a month’ – 2.51 (p=0.001), ‘several times a year’ – 3.99 (pConclusion. A low seizure frequency is a protective predictor of a positive response to drug therapy in patients with MTLE and FEOL, whereas the presence of a brain tumour and dialeptic seizures reduces the likelihood of achieving seizure control.
- 20 June 2026
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 18 (3)
Predictors of treatment efficacy in mesial temporal lobe epilepsy and focal epilepsies of other localisations
Mesial temporal lobe epilepsy (MTLE) is characterised by a high rate of drug resistance; however, it remains difficult to predict an individual’s response to treatment at an early stage. There is a need to optimise approaches to identifying predictors of treatment efficacy not only for MTLE but also for focal epilepsies of other localisation (FEOL). Objective: to identify clinical, anamnestic and neuroimaging predictors of response to drug therapy in patients with MTLE and FEOL, and to identify factors that do not have independent prognostic value. Material and methods. A retrospective analysis of a database of patients with focal epilepsy was conducted. Binary logistic regression was used to develop a prognostic model. Results. In the MTLE group (n=297), remission was achieved in 29% of patients, which is significantly lower than in the FEOL group (n=340) – 38.5% (p0.05). According to binary logistic regression (n=540; 36.1% – no positive effect, 63.9% – positive effect), after stepwise exclusion of non-informative predictors, three independent factors remained in the final model. Rare attacks increased the odds of a positive clinical effect (remission or a reduction in attack frequency by more than 50%): the odds ratio (OR) for the categories ‘several times a month’ – 2.51 (p=0.001), ‘several times a year’ – 3.99 (pConclusion. A low seizure frequency is a protective predictor of a positive response to drug therapy in patients with MTLE and FEOL, whereas the presence of a brain tumour and dialeptic seizures reduces the likelihood of achieving seizure control.
- 1 June 2026
- Published by Springer Nature in Neuroscience and Behavioral Physiology
- Vol. 56 (5) , 877-882
Features of Poststroke Speech Disorders and the Prospects of Mirror Therapy in the Recovery of Patients
- 1 June 2026
- Published by Springer Nature in Neuroscience and Behavioral Physiology
- Vol. 56 (5) , 877-882
Features of Poststroke Speech Disorders and the Prospects of Mirror Therapy in the Recovery of Patients
- 1 June 2026
- Published by MEDIKON LLC in Comorbidity neurology
- Vol. 3 (2)
The Effectiveness of a Non-Invasive Brain–Computer Interface Combined with Hand Vibration Stimulation in the Rehabilitation of Patients with Severe Post-Stroke Paresis
INTRODUCTION. The use of neurotechnology, the brain–computer interface (BCI), based on the motor imagery (MI), occupies one of the leading places in terms of effectiveness in neurorehabilitation. At the same time, various types of feedback in the BCI system are being developed and actively used in the rehabilitation process. The feedback targets the visual, proprioceptive, or auditory sensory system, and may employ a multimodal approach depending on the rehabilitation paradigm. Much attention of researchers is attracted to using touch, sensation of touch, force, and vibration as reinforcement signals via haptic feedback technology AIM. To evaluate the effectiveness of the integration of haptic biofeedback into BCI technology in patients with arm paresis in the recovery period after a stroke. MATERIALS AND METHODS. Eighteen patients suffering from chronic stroke (5 females and 13 males) participated in the study. The patients participated in motor imagery BCI trainings and were split into two groups according to the feedback type. The first group (9 patients, age 59,2 ± 10,6, time since stroke 10,4 ± 2,3 month) received haptic feedback via vibrating stimulation of palm surface and the second group (9 patients, age 59,2 ± 10,6, time since stroke 12 ± 9,8 month) received proprioceptive feedback via palm opening actuation with a robotic actuator. All patients received pharmacological therapy as part of secondary stroke prevention; rehabilitation interventions included therapeutic exercise, physiotherapy procedures, massage, and speech therapy sessions. RESULTS AND DISCUSSION. In group 1, motor function improved according to the Fugl-Meyer (FM), ARAT scales from 18 [14; 24] to 30 [20;30], with 2[1; 5] 3 [2; 8] points, respectively. In the 2nd group from 20 [17; 23] to 23[19; 27] on the FM scale, from 2 [1; 6] to 4 [3; 8] points on the ARAT scale. If we consider the 1st group as a "case" and the 2nd as a "control", then after adjusting for the initial FM (ANCOVA), we obtained a difference in the indicator (Δ) of the FM scale of 3.2 points (p = 0.046). The data obtained also demonstrates that BCI with vibrating rings is superior to BCI controlled by an exoskeleton in restoring motor functions, even with a pairwise comparison of similar patients. CONCLUSION. The use of BCI technology based on MI in combination with biofeedback in the form of vibration stimulation of the palm surfaces of the hands is a new promising method of rehabilitation of patients with severe hemiparesis after a stroke. KEYWORDS: brain–computer interface, biofeedback, exoskeleton, vibrational stimulation, rehabilitation after stroke, post-stroke hemiparesis
- 1 June 2026
- Published by MEDIKON LLC in Comorbidity neurology
- Vol. 3 (2)
The Effectiveness of a Non-Invasive Brain–Computer Interface Combined with Hand Vibration Stimulation in the Rehabilitation of Patients with Severe Post-Stroke Paresis
INTRODUCTION. The use of neurotechnology, the brain–computer interface (BCI), based on the motor imagery (MI), occupies one of the leading places in terms of effectiveness in neurorehabilitation. At the same time, various types of feedback in the BCI system are being developed and actively used in the rehabilitation process. The feedback targets the visual, proprioceptive, or auditory sensory system, and may employ a multimodal approach depending on the rehabilitation paradigm. Much attention of researchers is attracted to using touch, sensation of touch, force, and vibration as reinforcement signals via haptic feedback technology AIM. To evaluate the effectiveness of the integration of haptic biofeedback into BCI technology in patients with arm paresis in the recovery period after a stroke. MATERIALS AND METHODS. Eighteen patients suffering from chronic stroke (5 females and 13 males) participated in the study. The patients participated in motor imagery BCI trainings and were split into two groups according to the feedback type. The first group (9 patients, age 59,2 ± 10,6, time since stroke 10,4 ± 2,3 month) received haptic feedback via vibrating stimulation of palm surface and the second group (9 patients, age 59,2 ± 10,6, time since stroke 12 ± 9,8 month) received proprioceptive feedback via palm opening actuation with a robotic actuator. All patients received pharmacological therapy as part of secondary stroke prevention; rehabilitation interventions included therapeutic exercise, physiotherapy procedures, massage, and speech therapy sessions. RESULTS AND DISCUSSION. In group 1, motor function improved according to the Fugl-Meyer (FM), ARAT scales from 18 [14; 24] to 30 [20;30], with 2[1; 5] 3 [2; 8] points, respectively. In the 2nd group from 20 [17; 23] to 23[19; 27] on the FM scale, from 2 [1; 6] to 4 [3; 8] points on the ARAT scale. If we consider the 1st group as a "case" and the 2nd as a "control", then after adjusting for the initial FM (ANCOVA), we obtained a difference in the indicator (Δ) of the FM scale of 3.2 points (p = 0.046). The data obtained also demonstrates that BCI with vibrating rings is superior to BCI controlled by an exoskeleton in restoring motor functions, even with a pairwise comparison of similar patients. CONCLUSION. The use of BCI technology based on MI in combination with biofeedback in the form of vibration stimulation of the palm surfaces of the hands is a new promising method of rehabilitation of patients with severe hemiparesis after a stroke. KEYWORDS: brain–computer interface, biofeedback, exoskeleton, vibrational stimulation, rehabilitation after stroke, post-stroke hemiparesis
- 29 April 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (4) , 100-106
High effectiveness of cognitive rehabilitation in the late recovery period after revascularization
The article presents a clinical case of recovery of a patient after ischemic stroke with cognitive impairment, including aphasic disorders, and hemiparesis after systemic thrombolytic therapy and total selective endovascular mechanical thromboextraction, stent placement in the left ICA in the acute period, with a delayed start of further rehabilitation activities after nine months. The comprehensive rehabilitation program included classes with a computerized complex for training the upper limb with cognitive modules, modified mirror therapy, and classes with a speech therapist-neuropsychologist, and was aimed primarily at restoring cognitive functions, including all forms of impaired speech activity, through the cognitive load components of the program and restoring the movement function of the paretic right limb. Excellent outcomes were observed, confirmed by clinical and neuropsychological evaluations and electroencephalographic data, indicating a decrease in abnormal slow-wave activity and interhemispheric asymmetry after treatment.
- 29 April 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (4) , 100-106
High effectiveness of cognitive rehabilitation in the late recovery period after revascularization
The article presents a clinical case of recovery of a patient after ischemic stroke with cognitive impairment, including aphasic disorders, and hemiparesis after systemic thrombolytic therapy and total selective endovascular mechanical thromboextraction, stent placement in the left ICA in the acute period, with a delayed start of further rehabilitation activities after nine months. The comprehensive rehabilitation program included classes with a computerized complex for training the upper limb with cognitive modules, modified mirror therapy, and classes with a speech therapist-neuropsychologist, and was aimed primarily at restoring cognitive functions, including all forms of impaired speech activity, through the cognitive load components of the program and restoring the movement function of the paretic right limb. Excellent outcomes were observed, confirmed by clinical and neuropsychological evaluations and electroencephalographic data, indicating a decrease in abnormal slow-wave activity and interhemispheric asymmetry after treatment.
- 25 April 2026
- Published by IRBIS in Epilepsy and paroxysmal conditions
- Vol. 18 (1) , 72-81
Early provoking factors of epileptogenesis in mesial temporal lobe epilepsy
Mesial temporal lobe epilepsy (MTLE) is a severe form of focal epilepsy, often therapy-resistant, resulting from a long-term epileptogenesis. This clinical lecture examines the key early provoking factors of MTLE development: prolonged febrile seizures in childhood, neuroinfections, perinatal hypoxia, and traumatic brain injuries. The universal pathophysiological mechanisms triggered by these factors are analyzed in detail: excitotoxicity, neuroinflammation, blood-brain barrier disruption, aberrant neurogenesis, synaptic reorganization, and the central role of mammalian target of rapamycin (mTOR) signaling pathway hyperactivation. MTLE pathogenesis is explained from the perspective of the “dual/multiple hit” model, according to which the cumulative impact of several injuries leads to the depletion of the hippocampal compensatory capabilities and the formation of hippocampal sclerosis. The importance of comprehensive diagnosis, including detailed history collection, magnetic resonance imaging according to epileptology protocol, and the search for biomarkers is emphasized. Treatment prospects are related to shifting focus towards predictive and preventive therapy targeting key molecular pathways (pro-inflammatory cytokines, mTOR signaling), paving the way for personalized disease management.
- 25 April 2026
- Published by IRBIS in Epilepsy and paroxysmal conditions
- Vol. 18 (1) , 72-81
Early provoking factors of epileptogenesis in mesial temporal lobe epilepsy
Mesial temporal lobe epilepsy (MTLE) is a severe form of focal epilepsy, often therapy-resistant, resulting from a long-term epileptogenesis. This clinical lecture examines the key early provoking factors of MTLE development: prolonged febrile seizures in childhood, neuroinfections, perinatal hypoxia, and traumatic brain injuries. The universal pathophysiological mechanisms triggered by these factors are analyzed in detail: excitotoxicity, neuroinflammation, blood-brain barrier disruption, aberrant neurogenesis, synaptic reorganization, and the central role of mammalian target of rapamycin (mTOR) signaling pathway hyperactivation. MTLE pathogenesis is explained from the perspective of the “dual/multiple hit” model, according to which the cumulative impact of several injuries leads to the depletion of the hippocampal compensatory capabilities and the formation of hippocampal sclerosis. The importance of comprehensive diagnosis, including detailed history collection, magnetic resonance imaging according to epileptology protocol, and the search for biomarkers is emphasized. Treatment prospects are related to shifting focus towards predictive and preventive therapy targeting key molecular pathways (pro-inflammatory cytokines, mTOR signaling), paving the way for personalized disease management.